The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...

A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...

Over the last year, Viatris has been busy working to resolve FDA concerns at a critical drug manufacturing plant in India ...

The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...

The nod allows Hernexeos (zongertinib) to be used as an initial treatment option for NSCLC with HER2-activating mutations in ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. | Two years and five indications later ...